FKGK11 

FKGK11 is a potent and selective inhibitor of GVIA iPLA2 (Group VIA calcium-independent phospholipase A2). FKGK11 can be used for the research of ovarian cancer and neurological disorders such as peripheral nerve injury and multiple sclerosis^[1][2].

FKGK11 shows 99.4 ± 0.1% inhibition of GVIA iPLA2 and only 28 ± 1% for GV sPLA2 at 0.091 mole fraction^[1].
FKGK11 reduces adhesion, migration, and invasion of EOC (epithelial ovarian cancer) cells^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

FKGK11 inhibits tumor development in the xenograft mouse model^[2].
FKGK11 shows a significant increase in the number of macrophages and degenerating fibres with disrupted myelin sheaths in cPLA2 GIVA−/− mice and C57BL/6 mice^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

280.23

C₁₃H₁₃F₅O

1071000-98-0

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Kokotos G, et al. Potent and selective fluoroketone inhibitors of group VIA calcium-independent phospholipase A2. J Med Chem. 2010 May 13;53(9):3602-10.  [Content Brief]

  [2]. Yan Xu, et al. Abstract 3525: Targeting Group VIA phospholipase A2 using small molecules for ovarian cancer treatment. Cancer Res (2011) 71 (8_Supplement): 3525.

  [3]. López-Vales R, et al. Intracellular phospholipase A(2) group IVA and group VIA play important roles in Wallerian degeneration and axon regeneration after peripheral nerve injury. Brain. 2008 Oct;131(Pt 10):2620-31.  [Content Brief]